Press releaseGlobe Newswire
Vera Therapeutics
VERA · NASDAQ
$30.06+$1.14 (+3.94%)TodayMarket closed ·
Prev close $28.92
About VERA
- Employees
- 339
- Headquarters
- Brisbane California, California
- Listed
- May 14, 2021
- Sector
- Health Care
- Industry
- Biotechnology
- Website
- veratx.com
VERA key statistics
- Market cap
- 2.01B
- Price-earnings ratio
- 0.00
- Dividend yield
- —
- Average volume
- 1.76M
- Volume
- 1.19M
- Open price
- $28.92
- High today
- $30.52
- Low today
- $28.87
- 52 Week high
- $56.05
- 52 Week low
- $23.05
Vera Therapeutics (VERA) at a glance
As of Oct 20, 2026, Vera Therapeutics (VERA) shares are priced at $30.06, giving the company a market cap of 2.01B and a price-to-earnings ratio of 0.00.
Today the stock has traded between $28.87 and $30.52. The current price is 4.1% above the day's low and 1.5% below its high.
Volume so far is 1.19M shares, below the average of 1.76M shares a day.
Over the past year Vera Therapeutics has ranged from $23.05 to $56.05, and now sits 21% of the way up that range.
Vera Therapeutics met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$1.52 per share against an estimate of -$1.61.
The average analyst price target is $78.62, 161.5% above the current price, from 10 recent ratings.
Analyst ratings
Latest rating from each analyst over the past 12 months
80%of 10 analyst ratings say Buy
- Buy80.0%
- Hold20.0%
- Sell0.0%
Price target · 16 analystsAvg $78.62
- Low
- $34.34
- Now
- $30.06
- High
- $105.00
VERA earnings
Earnings per share, reported against the analyst estimate
Beat the estimate in 2 of the last 8 quarters, by 10.6% on average.
- Q3 FY24: reported -$0.85 per share against an estimate of -$0.6709
- Q4 FY24: reported -$0.72 per share against an estimate of -$0.8537
- Q1 FY25: reported -$0.81 per share against an estimate of -$0.7497
- Q2 FY25: reported -$1.20 per share against an estimate of -$0.8381
- Q3 FY25: reported -$1.26 per share against an estimate of -$1.16
- Q4 FY25: reported -$1.39 per share against an estimate of -$1.31
- Q1 FY26: reported -$1.69 per share against an estimate of -$1.35
- Q2 FY26: reported -$1.52 per share against an estimate of -$1.61
VERA news
- Avi Kapoor
Alignment Healthcare, RenX Enterprises And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
- Vandana Singh
What's Going on With Vera Therapeutics Stock on Tuesday?
- Press releaseGlobe Newswire
Vera Therapeutics to Participate at Upcoming Investor Conferences
- Press releaseGlobe Newswire
Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
- Vandana Singh
Why Is Vera Therapeutics Stock Gaining Tuesday?
FDA Approves Vera Therapeutics' Trutakna For Treatment Of Proteinuria In Adults With Primary Immunoglobulin A Nephropathy
- Vandana Singh
What's Going on with Vera Therapeutics Stock on Monday?
Similar companies
Companies in the same industry as Vera Therapeutics
Most active stocks
Highest trading volume today
- EARIEntertainment Arts Research$0.0003−16.67%
- SEIISharing Economy International$0.0004+100.00%
- NWGLCL Workshop Group$0.1522+27.90%
- TMSHTrans Global Assets$0.0002+0.00%
- AEFIAmerican EcoFuels$0.0007+0.00%
- CBDW1606$0.0002+0.00%
- FITYFifty 1 Labs$0.0001−66.67%
- PRSOPeraso$0.5914+54.13%
- SDSTStardust Power$0.02−23.66%
- SHFSSHF Holdings$0.0899−4.36%
- FRTTFort Technology$0.7121+32.63%
- CBDLCBD Life Sciences$0.0002−25.00%
Newly listed
Companies that went public in the past six weeks
- TCXBTCGX Acquisition Corp. II$10.56+1.54%
- CTYCITY THERAPEUTICS$20.83−2.94%
- IAMIambic Therapeutics$16.01−2.02%
- AMROAmaero$5.68+1.25%
- FLSCFrazier Life Sciences Acquisition Corp. II$10.28−0.10%
- TRXBTRex Bio$14.44−2.43%
- RTSNRetension Pharmaceuticals$16.18−0.92%
- PAXGUPine Tree Acquisition$9.98+0.00%
- PORTUSouthport Acquisition Corp. IIListed Oct 1, 2026
- CHWMChilwa Minerals$5.18+3.39%
- ACCVAccelevation Holdings$12.31−1.44%
- RZAIROZE AI$10.28+1.28%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.